RC
CDLX icon

Rangeley Capital’s Cardlytics CDLX Stock Holding History

Rangeley Capital’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,000
Closed -$237K – 78
2025
Q1 		$237K Sell
13,000
-19,000
-59% -$543K 0.25% 50
2024
Q4 		$1.19M Buy
+32,000
New +$1.22M 1.07% 28

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Rangeley Capital's CDLX Position: Q2 2025 in Review

Rangeley Capital sold out of Cardlytics (CDLX) in Q2 2025, closing a stake of 13,000 shares — an estimated $237K sold.

Rangeley Capital first reported a position in CDLX in Q4 2024 and held it in 2 quarters. The position peaked at $1.19M in Q4 2024. 89 funds tracked by Wall St. Rank hold CDLX as of Q2 2025.

  • Rangeley Capital reported no remaining Cardlytics position as of Q2 2025 after selling out during the quarter.
  • Rangeley Capital sold 13,000 Cardlytics shares in Q2 2025, an estimated $237K.
  • Rangeley Capital first reported a position in Cardlytics in Q4 2024 and held it in 2 quarters.
  • Rangeley Capital's Cardlytics position peaked at $1.19M in Q4 2024.
  • 89 funds tracked by Wall St. Rank held Cardlytics as of Q2 2025.

Based on Rangeley Capital's 13F filing for Q2 2025, filed 14 Aug 2025.